In today’s time, the genomics market in India is expanding at a breakneck pace. Bioinformatics is a well-established science that includes not just genomes, but also proteomics, drug design and discovery, and so on. In the recent past, there has been a major leap in the field of genomics, which has catapulted bio-informatics for sequencing analysis/ statistical as well as the development of new pipelines. Technological developments, increased research funding, and the presence of a large number of industry competitors and research institutes are fueling the market in India’s growth.
Aside from tool development, bioinformatics is essential for comprehending multiomics research and integrating genomes, proteomics, and other data sets. As a result, there is enormous opportunity for the creation of fresh tools and approaches. However, the obstacles in this market would be bridging the gap between knowing the client’s requirement, the wet lab operations, the desired deliverables, and leveraging the extensive tools available for getting the required outcomes.
One such frontrunner in the industry is Biokart India, which has made a name for itself as one of the pioneering Genomics companies with in-house processing capabilities. When it comes to understanding the requirements and offering tailor-made solutions that meet the researcher’s needs, the company is one of the top service providers. The company’s directors have been involved in Genomics-related bioinformatics from its inception, and they have more than 60 papers to their name.
"We have a specialized team of professionals in the field of wet lab, bioinformatics, and biology who collaborate to determine the best work-flow. Biokart India’s core team consists of molecular biologists, biotech engineers, system biology experts, and software developers. All members of the core team contribute a wealth of expertise in their respective industries, which allows us to not only address each service but also to grow and develop better and faster pipelines/tools”, says Vikram S, Founder at Biokart India.
“We strive to make our services more straight-forward, accessible, and dependable for our clients so that they may focus on their study with ease. We offer a comprehensive suite of molecular testing, applications, and analysis to scientists and researchers from a broad array/an array of institutes and organizations across the country”, Vikram adds.
A Robust Infrastructure In Place
Biokart India has a full-fledged facility in terms of wet lab that is required for handling and sequence
data creation. In-house capabilities range from Sanger Sequencing to NGS-based devices (illumina). In terms of computational infrastructure, there are several in-house servers that are used for a variety of functions, including storage and data processing. As a starting point, each server has 1TB of RAM and 128 threads.
When operating in the Genomics domain of research, Sanger services is the starting point for any researcher to understand a short sequence (i.e., a gene or a mutation of definite location). It is also the most accurate methodology in identifying the microorganisms provided the sample is of a pure culture (i.e. not a mixture of microorganisms). While NGS may be seen as a progression from Sanger sequencing, which allows microbe identification even if it is a combination of different cultures.
NGS may also be used to sequence the whole genome of a small organism such as bacteria or a huge creature such as humans or plants. It is also a critical tool for studying characteristics of gene expression using RNA sequencing technologies. Sanger/NGS applications, to name a few, are laboratory processes that generate sequencing reads in the form of ATGCs- bioinformatics is the perspective that makes sense and provides answers to the researcher's queries.
As the Biotech domain has grown and demand in the niche has increased, numerous new companies have sprouted, serving various sectors of the services. Biokart India Pvt Ltd is a stalwart in its area and will continue to be so because of its best-in-class service delivery. The company finds its edge over its peers due to its deep-rooted understanding of the requirements of the end users. The compan’s specialists comprehend the expectations and personalize our aid to generate the greatest results by having in-depth knowledge of accessible tools as well as coding and programming talents.
“We can confidently state that our experience with cross-platform analysis allows us to arrive at a realistic answer. We also take satisfaction in designing our own in-house pipelines that reduce processing time by more than tenfold while meeting or exceeding the gold standard tool set criteria. As a result, we strive to set new benchmarks in terms of client expectations”, highlights Vikram.
A Noteworthy Journey
In the year 2011, Biokart began operations as a distribution company. By 2013, the company had developed into a service provider, and it acquired its first Sanger Sequencing equipment in 2015, followed by the NGS machine (Illumina Miseq) in 2019. Recognizing these achievements, Biokart is proud to say that it is one of the few firms to have established a complete Sanger and NGS processing facility, as well as a cutting-edge Bioinformatics facility, without raising any funding or investments.
Biokart India is one of the rare firms that has established a comprehensive Sanger and NGS processing facility in-house, as well as full fledged bioinformatics facility without soliciting any cash or investment
The entire journey has been on an upward trend, with a major amount of earnings being pushed back into the company to fuel the rising need for growth and infrastructure. “We are very grateful to our esteemed clients, who have been crucial in our growth in terms of recommending us to their peers and enabling us to have a steady organic growth”, states Vikram.
The company is currently developing Artificial Intelligence and Machine Learning technologies and merging them with existing tools to handle various pandemic-related screening and monitoring for clinical genetic diagnostics. In the following year, it will also enter the field of clinical genetic diagnostics on a war footing.
“As a close-knit family, we at Biokart India work closely together. We look forward to developing freshmen out of college into full-fledged microbiologists and bio technologists. We believe in discipline and work together to achieve the organization's aims and objectives”, concludes Vikram.
We use cookies to ensure you get the best experience on our website. Read more...
